Altamira Therapeutics Ltd
NASDAQ:CYTO

Watchlist Manager
Altamira Therapeutics Ltd Logo
Altamira Therapeutics Ltd
NASDAQ:CYTO
Watchlist
Price: 0.1198 USD -60.07% Market Closed
Market Cap: 300k USD

Intrinsic Value

CYTO doesn't have a meaningful market cap.

The intrinsic value of one CYTO stock under the Base Case scenario is 13.5374 USD. Compared to the current market price of 0.1198 USD, Altamira Therapeutics Ltd is Undervalued by 99%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

CYTO Intrinsic Value
13.5374 USD
Undervaluation 99%
Intrinsic Value
Price
Worst Case
Base Case
Best Case
Compare CYTO to

Fundamental Analysis

Altamira Therapeutics Ltd
NASDAQ:CYTO
CH
Pharmaceuticals
Market Cap
319.9k USD
IPO
Aug 6, 2014
CH
Pharmaceuticals
Market Cap
319.9k USD
IPO
Aug 6, 2014
Price
$
CHf
Company Overview
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about CYTO?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Altamira Therapeutics Ltd

Current Assets 524k
Cash & Short-Term Investments 65.5k
Receivables 121.3k
Other Current Assets 337.2k
Non-Current Assets 7.5m
Long-Term Investments 2.5m
PP&E 417.6k
Intangibles 4.6m
Current Liabilities 1.2m
Accounts Payable 526.6k
Accrued Liabilities 577.9k
Other Current Liabilities 123.4k
Non-Current Liabilities 523k
Long-Term Debt 304.1k
Other Non-Current Liabilities 218.9k
Efficiency

Free Cash Flow Analysis
Altamira Therapeutics Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Altamira Therapeutics Ltd

Revenue
62.7k CHF
Operating Expenses
-583.4k CHF
Operating Income
-520.7k CHF
Other Expenses
513.4k CHF
Net Income
-7.2k CHF
Fundamental Scores

CYTO Profitability Score
Profitability Due Diligence

Altamira Therapeutics Ltd's profitability score is 28/100. The higher the profitability score, the more profitable the company is.

28/100
Profitability
Score

Altamira Therapeutics Ltd's profitability score is 28/100. The higher the profitability score, the more profitable the company is.

CYTO Solvency Score
Solvency Due Diligence

Altamira Therapeutics Ltd's solvency score is 41/100. The higher the solvency score, the more solvent the company is.

Long-Term Solvency
Low D/E
Low Altman Z-Score
Positive Net Debt
41/100
Solvency
Score

Altamira Therapeutics Ltd's solvency score is 41/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

CYTO Price Targets Summary
Altamira Therapeutics Ltd

There are no price targets for CYTO.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Dividends

Altamira Therapeutics Ltd
does not pay dividends
Shareholder Yield

Current shareholder yield for CYTO is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y